MX2024005107A - Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. - Google Patents

Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.

Info

Publication number
MX2024005107A
MX2024005107A MX2024005107A MX2024005107A MX2024005107A MX 2024005107 A MX2024005107 A MX 2024005107A MX 2024005107 A MX2024005107 A MX 2024005107A MX 2024005107 A MX2024005107 A MX 2024005107A MX 2024005107 A MX2024005107 A MX 2024005107A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
novel use
quinazolinone compound
fluoro
Prior art date
Application number
MX2024005107A
Other languages
English (en)
Inventor
Juergen Wichmann
Piergiorgio Francesco Tommaso Pettazzoni
Teixidor Ester Bonfill
Raffaella Iurlaro
Suárez Juan Seoane
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2024005107A publication Critical patent/MX2024005107A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a (3R)-N-[2-ciano-4-fluoro-3-(3-m etil-4-oxo-quinazolin-6-il)oxi-fenil]-3 fluoro-pirrolidin-1-sulfon amida o una sal de este farmacéuticamente aceptable, para su uso en el tratamiento de cáncer, en donde el paciente que tiene dicho cáncer se trató previamente con un inhibidor de BRAF diferente.
MX2024005107A 2021-11-04 2022-11-02 Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. MX2024005107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21206336 2021-11-04
PCT/EP2022/080475 WO2023078881A1 (en) 2021-11-04 2022-11-02 Novel use of quinazolinone compound for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024005107A true MX2024005107A (es) 2024-05-14

Family

ID=78516703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005107A MX2024005107A (es) 2021-11-04 2022-11-02 Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.

Country Status (9)

Country Link
EP (1) EP4426305A1 (es)
KR (1) KR20240105382A (es)
CN (1) CN118201615A (es)
AU (1) AU2022383040A1 (es)
CA (1) CA3230652A1 (es)
IL (1) IL312171A (es)
MX (1) MX2024005107A (es)
TW (1) TW202333707A (es)
WO (1) WO2023078881A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024105144A1 (en) * 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3000810B1 (en) 2002-03-13 2017-07-19 Array Biopharma, Inc. N3 alkylated benzimidazole derivative as mek inhibitor
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN114787156B (zh) 2019-12-10 2024-07-26 豪夫迈·罗氏有限公司 新颖甲基喹唑啉酮衍生物
KR102699226B1 (ko) * 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
AU2022289684A1 (en) * 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer

Also Published As

Publication number Publication date
KR20240105382A (ko) 2024-07-05
WO2023078881A1 (en) 2023-05-11
CN118201615A (zh) 2024-06-14
IL312171A (en) 2024-06-01
AU2022383040A1 (en) 2024-03-07
CA3230652A1 (en) 2023-05-11
EP4426305A1 (en) 2024-09-11
TW202333707A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
PH12018502355A1 (en) Enzyme inhibitors
EA202190630A1 (ru) Способы комбинированной терапии
MX2022006986A (es) Inhibidores de kras g12c.
MX2023007192A (es) Inhibidores de prmt5.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA202193015A1 (ru) Ингибиторы cdk
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MD3532459T2 (ro) Inhibitori ai LSD1 și utilizările medicale ale acestora
EA202190749A1 (ru) Способы комбинированной терапии
WO2018102687A3 (en) Combination therapy for treating cancer
AU2017261286A1 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
MX2022000143A (es) Metodos novedosos.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022000545A (es) Inhibidores de enzimas.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2022000811A (es) Inhibidores de enzimas.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.